559 results on '"Mok, T"'
Search Results
2. First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology
3. The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective
4. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
5. Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series
6. How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer
7. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
8. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
9. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
10. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
11. Supplement to: Osimertinib or platinum—pemetrexed in EGFR T790M—positive lung cancer.
12. Supplement to: Variant Creutzfeldt-Jakob disease in a patient with heterozygosity at PRNP codon 129.
13. Overview of current systemic management of EGFR-mutant NSCLC
14. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
15. Epigenomic analysis of lung adenocarcinoma reveals novel DNA methylation patterns associated with smoking
16. Anomalous Light Scattering by Topological PT-symmetric Particle Arrays
17. Supplement to: First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
18. Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042: 195TiP
19. NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC: 192TiP
20. LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations: 140PD
21. Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials: 141PD
22. Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6): 138PD
23. Being molecular in the molecular age
24. Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death
25. 4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A2 and its receptor
26. A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group
27. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
28. Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer
29. Safety profile of afatinib in first-line therapy of patients with metastatic EGFR mutation-positive (M+) non-small cell lung cancer (NSCLC): Comparative analysis of Asian and non-Asian patients from two randomized trials: ID 242
30. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy
31. Supplement to: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
32. PP01.47 HERTHENA-Lung02: A Randomized Phase 3 Study of Patritumab Deruxtecan vs Platinum-Based Chemotherapy in Locally Advanced or Metastatic EGFR-Mutated NSCLC After Progression with a Third-Generation EGFR TKI
33. The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: a randomised controlled trial
34. Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients
35. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer
36. Bilateral brachial neuropathy and acute aortic dissection due to giant cell arteritis
37. Familial occurrence of sequential B-cell lymphoma and myeloproliferative disease
38. A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity
39. P2.09-17 OSTARA: A Phase II Study of First-line Osimertinib Combined with Amivantamab in EGFRm Advanced Non-Small Cell Lung Cancer.
40. P2.06-05 Durvalumab ± Tremelimumab + Chemotherapy in 1L Metastatic NSCLC: Characterisation of patients with PFS ≥12 months in POSEIDON.
41. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma
42. Failure analysis of miniaturized multilayer ceramic capacitors in surface mount printed circuit board assemblies
43. OA15.04 Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC.
44. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy
45. Six month radiological and physiological outcomes in severe acute respiratory syndrome (SARS) survivors
46. Impact of Sjögrenʼs syndrome on oral health-related quality of life in southern Chinese
47. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)
48. An analysis of the antiemetic protection of metoclopramide plus dexamethasone in Chinese patients receiving moderately high emetogenic chemotherapy
49. Concurrent Chemotherapy-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: Progression-Free Survival Analysis of a Phase III Randomized Trial
50. Accuracy of automated three-dimensional ultrasound imaging technique for fetal head biometry.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.